Details for Patent: 8,062,667
✉ Email this page to a colleague
Which drugs does patent 8,062,667 protect, and when does it expire?
Patent 8,062,667 protects QUILLIVANT XR, DYANAVEL XR, KARBINAL ER, ONYDA XR, and TUZISTRA XR, and is included in five NDAs.
This patent has twenty-one patent family members in fourteen countries.
Summary for Patent: 8,062,667
| Title: | Modified release formulations containing drug-ion exchange resin complexes |
| Abstract: | A coated drug-ion exchange resin complex comprising a core composed of a drug complexed with a pharmaceutically acceptable ion-exchange resin is provided. The drug-ion exchange resin complex is in admixture with a release retardant. The coating is a polyvinyl acetate polymer and a plasticizer. Methods of making and products containing this coated complex are described. |
| Inventor(s): | Mehta; Ketan (Cranbury, NJ), Tu; Yu-Hsing (West Windsor, NJ) |
| Assignee: | Tris Pharma, Inc. (Monmouth Junction, NJ) |
| Application Number: | 11/724,966 |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 8,062,667 |
|
Patent Claim Types: see list of patent claims | Composition; Process; Formulation; |
Drugs Protected by US Patent 8,062,667
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Nextwave | QUILLIVANT XR | methylphenidate hydrochloride | FOR SUSPENSION, EXTENDED RELEASE;ORAL | 202100-001 | Sep 27, 2012 | AB | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
| Tris Pharma Inc | DYANAVEL XR | amphetamine; amphetamine aspartate/dextroamphetamine sulfate | SUSPENSION, EXTENDED RELEASE;ORAL | 208147-001 | Oct 19, 2015 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | ||||
| Aytu | KARBINAL ER | carbinoxamine maleate | SUSPENSION, EXTENDED RELEASE;ORAL | 022556-001 | Mar 28, 2013 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | ||||
| Tris Pharma Inc | ONYDA XR | clonidine hydrochloride | SUSPENSION, EXTENDED RELEASE;ORAL | 217645-001 | May 24, 2024 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | ||||
| Tris Pharma Inc | TUZISTRA XR | chlorpheniramine polistirex; codeine polistirex | SUSPENSION, EXTENDED RELEASE;ORAL | 207768-001 | Apr 30, 2015 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 8,062,667
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Austria | E536867 | ⤷ Sign Up | |||
| Australia | 2007227569 | ⤷ Sign Up | |||
| Brazil | PI0709606 | ⤷ Sign Up | |||
| Canada | 2645855 | ⤷ Sign Up | |||
| China | 101400343 | ⤷ Sign Up | |||
| China | 102488652 | ⤷ Sign Up | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
